DRG Market Assessment reports

Hemophilia is a monogenic bleeding disorder occurring primarily in males. In hemophilia A and hemophilia B, factor VIII or factor IX (respectively) is either absent or deficient in function…

This quarterly report series examines the current management of unresectable/metastatic malignant melanoma in the United States from the perspective of medical oncologists and explores trends in…

The TreatmentTrends: Psoriasis 2015 (US) report explores treatment dynamics and their evolution among 100 U.S. dermatologists, through comprehensive primary research methods. The use of biologic…

Last Updated 16 December 2015 Schizophrenia is an often disabling psychiatric disease whose core treatment consists of years up to a lifetime of treatment with antipsychotics (older typical…

Last Updated 16 December 2015 Parkinson’s disease (PD) is one of the most common chronic neurodegenerative diseases in the elderly; its prevalence is expected to grow 2% annually in the major…

Neuropathic pain (NP) is a prominent form of pain associated with a variety of diseases and conditions, including cancer, diabetes, herpes zoster, chronic back pain, and multiple sclerosis. A…

Duchenne muscular dystrophy (DMD) is the most common form of childhood muscular dystrophies. DMD manifests as muscle degeneration and weakness, and it is histologically characterized by features…

The wide array of disease-modifying therapies (DMTs) now available for the treatment of multiple sclerosis (MS) in the major European markets (EU5; France, Germany, Italy, Spain, and the United…

Last Updated 14 December 2015 The rheumatoid arthritis (RA) therapy market has matured to the point that TNF-α inhibitors have become firmly established as first-line biological agents, leaving…

Last Updated 14 December 2015 The large therapeutic market for chronic obstructive pulmonary disease (COPD), a disease that is closely associated with smoking, continues to expand. The prevalence…

The entrenched positioning of biologics (in particular, tumor necrosis factor-alpha [TNF-alpha] inhibitors) to treat moderate-to-severe rheumatoid arthritis (RA) has generated a multi-billion-…

The prevalence of difficult-to-treat infections is increasing worldwide, despite regional variations in the etiological pathogens. This report provides an extensive overview of the use of…